Skip to Content

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • RFA-CA-07-505: The American College of Radiology Imaging Network (ACRIN) (Limited Competition U01)

    • Release Date: February 09, 2007
    • Application Receipt Date: April 10, 2007
    • Contacts:

      Barbara A. Galen, MSN, CRNP, CNMT, Tel: 301-594-5225, e-mail:

    The Cancer Imaging Program, Division of Cancer Diagnosis and Treatment, the National Cancer Institute (NCI), invites applications for a limited competition Request for Applications (RFA) for the continued support of a unique, multi-center imaging network -- the American College of Radiology Imaging Network (ACRIN; hereafter referred to as the "Network"). The overall objective of this limited competition RFA is to improve the use of imaging in cancer research and cancer care management through further support for the activities of the Network. The Network should continue to focus on investigator-initiated research involving key aspects of imaging technology assessment in oncology. Eligible organizations include the current recipients of the ACRIN awards, which are the American College of Radiology-Philadelphia Headquarters and the Brown University-Biostatistics and Data Management Center. The eligible applicants are expected to submit two linked applications (Network Headquarters application and Biostatistics and Data Management Center application). Both applications will be reviewed together and will receive a single score.


  • PAR-06-406: In Vivo Cellular and Molecular Imaging Centers (ICMICs)[P50]

    • Release Date: May 09, 2006
    • Application Receipt Date: August 16, 2006; August 16, 2007
    • Expiration Date: August 17, 2007
    • Contacts:

      Anne E. Menkens, NCI, Phone: 301-496-9531, Email:

    This is a reissue of PAR-04-069, which was previously released February 27, 2004.

    The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the progress in molecular imaging as the basis for the extraordinary, non-invasive and quantitative analytical tools useful in the diagnosis and treatment of cancer as well as in the laboratory environment to interrogate biological pathways relevant to cancer. The Cancer Imaging Program of the NCI solicits new or competing applications for P50 Research Center Grants for In Vivo Cellular and Molecular Imaging Centers (ICMICs). The program will fund the 5-year P50 ICMIC grants to support interdisciplinary scientific teams conducting cutting-edge cancer molecular imaging research with clinical relevance. ICMIC funding is designed to: (1) support unique core facilities; (2) enable the awardees to initiate pilot research in new promising directions; and (3) provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging.

    See full description in NIH Guide:PAR-06-406

  • PA-06-398: Novel Technologies For In Vivo Imaging (R21/R133)

    This Program Announcement (PA) replaces PA-04-095.

    Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits Phased Innovation (R21/R33) grant applications from applicant organizations that propose the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This FOA is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality.

    See full description in NIH Guide:PA-06-398

    What is the R21 grant mechanism?
    What is the R33 grant mechanism?